BACKGROUND: @entity2008 are one of the most important prognostic factors in @entity3052 ( @entity3052 ). However, only a limited number of @entity1 have such informative @entity2008 . The prognostic value of immunophenotyping in this disease is still unclear. METHODS: Seven hundred and eighty-three newly diagnosed @entity3052 @entity1 treated in the German SHG- @entity3052 trials in 1991 and 1996 were analyzed with a panel of 33 antibodies. Expression was correlated to overall survival, complete remission-rate, and complete remission duration, and tested in a multivariate analysis including other clinical and biological markers. RESULTS: With a median follow-up of 4.3 years, @entity1 with @entity3052 blasts negative for @entity6460 , @entity9536 , @entity10793 , @entity2280 , and @entity1427 , or positive for @entity5824 , @entity1116 , @entity3053 , @entity10685 , and @entity3335 had superior overall survival. This effect was associated with a significantly higher complete remission rate ( @entity10793 , @entity2280 , @entity1427 , and @entity10685 ) or a longer complete remission duration ( @entity6460 , @entity9536 , and @entity10685 ). Cox-regression analysis, including cytogenetic, morphologic, and biologic parameters showed @entity6460 , @entity10793 , @entity2280 , and @entity10685 as independent factors for overall survival. These markers were used for a prognostic score. @entity1 were pooled in three groups with highly significant differences of overall survival. The prognostic relevance of this score was confirmed in @entity1 with normal karyotype and/or in younger @entity1 </= 60 years. CONCLUSIONS: Immunophenotyping is not only helpful for diagnosis but is of independent significance for prognosis, and may be useful for risk stratification in @entity3052 @entity1 .

Immunophenotyping is an independent factor for risk stratification in XXXX .

@entity1 :: ('9606', 'Species') :: ['Patients', 'patients'] @entity6460 :: ('928', 'Gene') :: ['CD9'] @entity10793 :: ('290', 'Gene') :: ['CD13'] @entity3335 :: ('4353', 'Gene') :: ['MPO'] @entity10685 :: ('2209', 'Gene') :: ['CD64'] @entity5824 :: ('2526', 'Gene') :: ['CD15'] @entity3052 :: ('MESH:D015470', 'Disease') :: ['acute myeloid leukemia', 'AML'] @entity3053 :: ('952', 'Gene') :: ['CD38'] @entity2280 :: ('947', 'Gene') :: ['CD34'] @entity1427 :: ('3674', 'Gene') :: ['CD41'] @entity9536 :: ('3684', 'Gene') :: ['CD11b'] @entity2008 :: ('MESH:D002869', 'Disease') :: ['chromosomal abnormalities', 'Chromosomal abnormalities'] @entity1116 :: ('945', 'Gene') :: ['CD33']
@entity3052 :: (MESH:D015470,Disease) :: ['AML']
